279 related articles for article (PubMed ID: 32124385)
21. Novel splice-switching oligonucleotide promotes BRCA1 aberrant splicing and susceptibility to PARP inhibitor action.
Smith LD; Leme de Calais F; Raponi M; Mellone M; Buratti E; Blaydes JP; Baralle D
Int J Cancer; 2017 Apr; 140(7):1564-1570. PubMed ID: 27997688
[TBL] [Abstract][Full Text] [Related]
22. Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms.
de la Hoya M; Soukarieh O; López-Perolio I; Vega A; Walker LC; van Ierland Y; Baralle D; Santamariña M; Lattimore V; Wijnen J; Whiley P; Blanco A; Raponi M; Hauke J; Wappenschmidt B; Becker A; Hansen TV; Behar R; Investigators K; Niederacher D; Arnold N; Dworniczak B; Steinemann D; Faust U; Rubinstein W; Hulick PJ; Houdayer C; Caputo SM; Castera L; Pesaran T; Chao E; Brewer C; Southey MC; van Asperen CJ; Singer CF; Sullivan J; Poplawski N; Mai P; Peto J; Johnson N; Burwinkel B; Surowy H; Bojesen SE; Flyger H; Lindblom A; Margolin S; Chang-Claude J; Rudolph A; Radice P; Galastri L; Olson JE; Hallberg E; Giles GG; Milne RL; Andrulis IL; Glendon G; Hall P; Czene K; Blows F; Shah M; Wang Q; Dennis J; Michailidou K; McGuffog L; Bolla MK; Antoniou AC; Easton DF; Couch FJ; Tavtigian S; Vreeswijk MP; Parsons M; Meeks HD; Martins A; Goldgar DE; Spurdle AB
Hum Mol Genet; 2016 Jun; 25(11):2256-2268. PubMed ID: 27008870
[TBL] [Abstract][Full Text] [Related]
23. Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene.
Bonnet C; Krieger S; Vezain M; Rousselin A; Tournier I; Martins A; Berthet P; Chevrier A; Dugast C; Layet V; Rossi A; Lidereau R; Frébourg T; Hardouin A; Tosi M
J Med Genet; 2008 Jul; 45(7):438-46. PubMed ID: 18424508
[TBL] [Abstract][Full Text] [Related]
24. Differential Sensitivity of Germline and Somatic
Vendrell JA; Ban IO; Solassol I; Audran P; Cabello-Aguilar S; Topart D; Lindet-Bourgeois C; Colombo PE; Legouffe E; D'Hondt V; Fabbro M; Solassol J
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762485
[TBL] [Abstract][Full Text] [Related]
25. Analysis of 30 putative BRCA1 splicing mutations in hereditary breast and ovarian cancer families identifies exonic splice site mutations that escape in silico prediction.
Wappenschmidt B; Becker AA; Hauke J; Weber U; Engert S; Köhler J; Kast K; Arnold N; Rhiem K; Hahnen E; Meindl A; Schmutzler RK
PLoS One; 2012; 7(12):e50800. PubMed ID: 23239986
[TBL] [Abstract][Full Text] [Related]
26. Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide.
Hirotsu Y; Schmidt-Edelkraut U; Nakagomi H; Sakamoto I; Hartenfeller M; Narang R; Soldatos TG; Kaduthanam S; Wang X; Hettich S; Brock S; Jackson DB; Omata M
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486089
[No Abstract] [Full Text] [Related]
27. [BRCA diagnostics of ovarian cancer : Molecular tumor testing since the introduction of PARP inhibitor therapy].
Löser H; Heydt C; Büttner R; Markiefka B
Pathologe; 2017 Mar; 38(2):117-126. PubMed ID: 28258387
[TBL] [Abstract][Full Text] [Related]
28. Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression.
Chen X; Truong TT; Weaver J; Bove BA; Cattie K; Armstrong BA; Daly MB; Godwin AK
Hum Mutat; 2006 May; 27(5):427-35. PubMed ID: 16619214
[TBL] [Abstract][Full Text] [Related]
29. Thorough in silico and in vitro cDNA analysis of 21 putative BRCA1 and BRCA2 splice variants and a complex tandem duplication in BRCA2 allowing the identification of activated cryptic splice donor sites in BRCA2 exon 11.
Baert A; Machackova E; Coene I; Cremin C; Turner K; Portigal-Todd C; Asrat MJ; Nuk J; Mindlin A; Young S; MacMillan A; Van Maerken T; Trbusek M; McKinnon W; Wood ME; Foulkes WD; Santamariña M; de la Hoya M; Foretova L; Poppe B; Vral A; Rosseel T; De Leeneer K; Vega A; Claes KBM
Hum Mutat; 2018 Apr; 39(4):515-526. PubMed ID: 29280214
[TBL] [Abstract][Full Text] [Related]
30. Implementation of BRCA mutations testing in formalin-fixed paraffin-embedded (FFPE) samples of different cancer types.
Zannini G; Facchini G; De Sio M; De Vita F; Ronchi A; Orditura M; Vietri MT; Ciardiello F; Franco R; Accardo M; Zito Marino F
Pathol Res Pract; 2023 Mar; 243():154336. PubMed ID: 36736144
[TBL] [Abstract][Full Text] [Related]
31. Detection of somatic BRCA1/2 mutations in ovarian cancer - next-generation sequencing analysis of 100 cases.
Koczkowska M; Zuk M; Gorczynski A; Ratajska M; Lewandowska M; Biernat W; Limon J; Wasag B
Cancer Med; 2016 Jul; 5(7):1640-6. PubMed ID: 27167707
[TBL] [Abstract][Full Text] [Related]
32. PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor Response.
Riad A; Gitto SB; Lee H; Winters HD; Martorano PM; Hsieh CJ; Xu K; Omran DK; Powell DJ; Mach RH; Makvandi M
Molecules; 2020 Dec; 25(24):. PubMed ID: 33352773
[TBL] [Abstract][Full Text] [Related]
33. A reliable method for the detection of BRCA1 and BRCA2 mutations in fixed tumour tissue utilising multiplex PCR-based targeted next generation sequencing.
Ellison G; Huang S; Carr H; Wallace A; Ahdesmaki M; Bhaskar S; Mills J
BMC Clin Pathol; 2015; 15():5. PubMed ID: 25859162
[TBL] [Abstract][Full Text] [Related]
34. Alternative splicing of the multidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20.
He X; Ee PL; Coon JS; Beck WT
Clin Cancer Res; 2004 Jul; 10(14):4652-60. PubMed ID: 15269137
[TBL] [Abstract][Full Text] [Related]
35. Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer.
Ryu JS; Lee HY; Cho EH; Yoon KA; Kim MK; Joo J; Lee ES; Kang HS; Lee S; Lee DO; Lim MC; Kong SY
Cancer Sci; 2020 Oct; 111(10):3912-3925. PubMed ID: 32761968
[TBL] [Abstract][Full Text] [Related]
36. [Testing of mutations in BRCA1 and BRCA2 genes in tumor tissues - possibilities and limitations].
Vošmiková H; Ryška A; Sieglová K; Laco J
Cesk Patol; 2016; 52(4):210-214. PubMed ID: 27869447
[TBL] [Abstract][Full Text] [Related]
37. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
38. Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members.
Thomassen M; Blanco A; Montagna M; Hansen TV; Pedersen IS; Gutiérrez-Enríquez S; Menéndez M; Fachal L; Santamariña M; Steffensen AY; Jønson L; Agata S; Whiley P; Tognazzo S; Tornero E; Jensen UB; Balmaña J; Kruse TA; Goldgar DE; Lázaro C; Diez O; Spurdle AB; Vega A
Breast Cancer Res Treat; 2012 Apr; 132(3):1009-23. PubMed ID: 21769658
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive prediction of mRNA splicing effects of BRCA1 and BRCA2 variants.
Mucaki EJ; Ainsworth P; Rogan PK
Hum Mutat; 2011 Jul; 32(7):735-42. PubMed ID: 21523855
[TBL] [Abstract][Full Text] [Related]
40. RNA analysis of eight BRCA1 and BRCA2 unclassified variants identified in breast/ovarian cancer families from Spain.
Campos B; Díez O; Domènech M; Baena M; Balmaña J; Sanz J; Ramírez A; Alonso C; Baiget M
Hum Mutat; 2003 Oct; 22(4):337. PubMed ID: 12955719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
